elezanumab

Ligand id: 9290

Name: elezanumab

Immunopharmacology Comments
Elezanumab (ABT-555) is clinical candidate monoclonal anti-RGMA antibody, that is in Phase 1 development for MS. Inhibition of RGMA is expected to concurrently block autoimmune demyelination and axon injury to reduce severity of MS pathology.